AT-101, a Pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 680-687

  Moretti, Luigi ^a   Li, Bo ^a   Kim, Kwang Woon ^a   Chen, Heidi ^b   Lu, Bo ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Lung cancer; Radiotherapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ISOSORBIDE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIZATION; TREATMENT RESPONSE;

EID: 77951878281     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d6e08e     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885.
3. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res 2000;301:133-142.
4. Pegoraro L, Palumbo A, Erikson J, et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 1984;81:7166-7170.
5. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
6. Hanada M, Aime-Sempe C, Sato T, et al. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995;270:11962-11969.
7. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994;54:5501-5507.
8. Olopade OI, Adeyanju MO, Safa AR, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997;3:230-237.
9. Hague A, Moorghen M, Hicks D, et al. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-3370.
10. Ikegaki N, Katsumata M, Minna J, et al. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8.
11. King ED, Matteson J, Jacobs SC, et al. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996;155:316-320.
12. Petros AM, Nettesheim DG, Wang Y, et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 2000;9:2528-2534.
13. Schott AF, Apel IJ, Nunez G, et al. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 1995;11:1389-1394.
14. Verrier F, Deniaud A, Lebras M, et al. Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene 2004;23:8049-8064.
15. Wolter KG, Wang SJ, Henson BS, et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 2006;8:163-172.
16. Kline MP, Rajkumar SV, Timm MM, et al. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol 2008;36:568-576.
17. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(a')-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4:13-21.
18. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-6142.
19. Balakrishnan K, Wierda WG, Keating MJ, et al. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-1980.
20. Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008;7:2192-2202.
21. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypolinduced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103.
22. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
24. Minn AJ, Rudin CM, Boise LH, et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86:1903-1910.
25. Amundson SA, Myers TG, Scudiero D, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-6110.
26. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008;68:2321-2328.
27. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-388.
28. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399.
29. Wang S, Jiang F, Bai L, et al. Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis. J Clin Oncol 2009;27:e14611.
30. Macoska JA, Adsule S, Tantivejkul K, et al.-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res 2008;58:323-331.
31. Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16:1030-1039.